Edwards D J, Sorisio D A, Knopf S
Department of Pharmacology-Physiology, University of Pittsburgh School of Dental Medicine, PA 15261.
Biochem Pharmacol. 1989 Sep 15;38(18):2957-65. doi: 10.1016/0006-2952(89)90003-8.
The beta 2-adrenoceptor agonist, clenbuterol (initially 5 mg/kg), was found to significantly reduce plasma tyrosine and raise brain tryptophan levels (P less than 0.01). By comparison, decreases in plasma tryptophan and increases in brain tyrosine were small and often nonsignificant. Amino acid levels measured in different brain regions revealed that the elevations were similar among the cerebellum, striatum, and cortex. These effects were partially blocked by propanolol but not by atenolol. The ED50 was estimated from dose-response curves to be about 0.05 mg/kg for both the decrease in plasma tyrosine and the increase in brain tryptophan. The effects of low doses of clenbuterol were prevented completely by propranolol. Peripheral organs displayed strikingly different patterns of change in amino acid concentrations. Only the spleen had any accumulation of tryptophan, but that was much less than in brain. In contrast, tyrosine and tryptophan were decreased in heart and unaltered in liver; tyrosine was decreased in lung. The elevation in brain tryptophan levels was attenuated by the beta 2-antagonist, ICI 118,551, but not by the beta 1-antagonist, betaxolol; but the reduction in plasma tyrosine was unaffected by either drug. The serotonin antagonist, methysergide, failed to block the effects of clenbuterol. We conclude that changes in amino acid concentrations produced by clenbuterol are mediated by beta 2-adrenoceptor stimulation. Although the increases in brain tyrosine and tryptophan were similar to increases in the plasma ratios of these amino acids to the sum of the other large neutral amino acids competing for transport into the brain, the disparity between the effects of ICI 118,551 in brain and plasma suggests that clenbuterol may also have a direct action in brain to regulate levels of aromatic amino acids. Since clenbuterol has been purported to have an antidepressant effect and since other antidepressants also increase brain tryptophan, this may be a common feature of antidepressant drug action.
β2 - 肾上腺素能受体激动剂克仑特罗(初始剂量为5毫克/千克)被发现能显著降低血浆酪氨酸水平并提高脑内色氨酸水平(P < 0.01)。相比之下,血浆色氨酸水平的降低和脑内酪氨酸水平的升高幅度较小且常常无显著差异。在不同脑区测量的氨基酸水平显示,小脑、纹状体和皮质中的升高情况相似。这些效应部分被普萘洛尔阻断,但未被阿替洛尔阻断。根据剂量 - 反应曲线估计,血浆酪氨酸水平降低和脑内色氨酸水平升高的半数有效剂量(ED50)约为0.05毫克/千克。低剂量克仑特罗的效应被普萘洛尔完全阻断。外周器官氨基酸浓度的变化模式显著不同。只有脾脏有任何色氨酸积累,但远少于脑内。相反,心脏中的酪氨酸和色氨酸减少,肝脏中的不变;肺中的酪氨酸减少。β2 - 拮抗剂ICI 118,551可减弱脑内色氨酸水平的升高,但β1 - 拮抗剂倍他洛尔则无此作用;而两种药物均不影响血浆酪氨酸水平的降低。5 - 羟色胺拮抗剂麦角新碱未能阻断克仑特罗的效应。我们得出结论,克仑特罗引起的氨基酸浓度变化是由β2 - 肾上腺素能受体刺激介导的。尽管脑内酪氨酸和色氨酸的增加与这些氨基酸在血浆中与其他竞争转运入脑的大中性氨基酸总和的比例增加相似,但ICI 118,551在脑内和血浆中的效应差异表明,克仑特罗在脑内可能也有直接作用来调节芳香族氨基酸水平。由于克仑特罗据称具有抗抑郁作用,且其他抗抑郁药也会增加脑内色氨酸,这可能是抗抑郁药物作用的一个共同特征。